Compare SSMR & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSMR | ALMR |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Laboratory Analytical Instruments |
| Sector | Basic Materials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2026 | 2026 |
| Metric | SSMR | ALMR |
|---|---|---|
| Price | $11.02 | $26.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $19.08 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 1.1M | 649.8K |
| Earning Date | 11-12-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $64.80 |
| Revenue Next Year | N/A | $37.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.63 | $21.58 |
| 52 Week High | $19.61 | $39.61 |
| Indicator | SSMR | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 37.63 | 40.49 |
| Support Level | $11.00 | $23.87 |
| Resistance Level | $15.17 | $29.06 |
| Average True Range (ATR) | 1.12 | 2.34 |
| MACD | -0.09 | -0.28 |
| Stochastic Oscillator | 11.96 | 20.17 |
Sunshine Silver Mining & Refining Co is a mining exploration and development company. It owns and develops the Sunshine Mine, the Sunshine Silver/Copper Refinery, and related facilities, including the Sunshine Tailings Storage Facility and historical antimony refinery grounds. The Sunshine Mine is a permitted past-producing silver mine in the United States that has historically produced silver, antimony, copper, and lead.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.